Compositions and methods for treatment of thyroid eye disease

Abstract

Antibodies and compositions against IGF-1R and uses thereof are provided herein.

What is claimed is: 
     
         1 . An isolated antibody comprising a light chain having the amino acid sequence of SEQ ID NO: 3 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 83. 
     
     
         2 . A pharmaceutical composition suitable for subcutaneous administration comprising the antibody of  claim 1 . 
     
     
         3 . A pharmaceutical composition suitable for intravenous administration comprising the antibody of  claim 1 . 
     
     
         4 . A pharmaceutical composition comprising the antibody of  claim 1  and a pharmaceutically acceptable excipient. 
     
     
         5 . A method of treating thyroid eye disease in a subject, the method comprising administering a pharmaceutical composition comprising the antibody of  claim 1 . 
     
     
         6 . The method of  claim 5 , wherein the pharmaceutical composition is administered intravenously. 
     
     
         7 . The method of  claim 5 , wherein the pharmaceutical composition is administered subcutaneously. 
     
     
         8 . The method of  claim 5 , wherein said antibody is administered at a dosage of about 1 mg/kg to about 5 mg/kg, about 5 mg/kg to about 10 mg/kg, about 10 mg/kg to about 20 mg/kg, about 20 mg/kg to about 30 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, or about 30 mg/kg of the antibody as a first dose. 
     
     
         9 . The method of  claim 5 , wherein said antibody is administered at a dosage of about 10 mg/kg to about 20 mg/kg of antibody as a first dose. 
     
     
         10 . The method of  claim 8 , wherein said antibody is administered at a dosage of about 1 mg/kg to about 10 mg/kg, about 2 mg/kg to about 5 mg/kg, or about 5 mg/kg to about 20 mg/kg of antibody in subsequent doses. 
     
     
         11 . The method of  claim 5 , wherein said antibody is administered in the following amounts: about 10 mg/kg antibody as a first dose; and about 20 mg/kg antibody in subsequent doses. 
     
     
         12 . The method of  claim 10 , wherein said subsequent doses are administered every three weeks, every four weeks, every five weeks, every six weeks, every seven weeks, or every eight weeks.